Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:06 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 6,228 matching trials from the local directory fallback.

Filters: Condition: Cancer Clear all

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Digital Rectal Examination, Echocardiography Test, Electronic Health Record Review, Endoscopic Procedure, Magnetic Resonance Imaging, Multigated Acquisition Scan, Patient Observation, Resection, Zanidatamab; Procedure · Other · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: BCG-Refractory Bladder Cancer, BCG-Unresponsive Bladder Cancer, Bladder Cancer, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype), Non-Muscle Invasive Bladder Cancer (NMIBC), T1 Stage Bladder Cancer, Ta Stage Bladder Cancer, Urothelial Carcinoma
Interventions: Intravesical Gemcitabine and Docetaxel; Drug
Lead sponsor: Michael A. O'Donnell; Other
Eligibility: 18 Years to 99 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hearing Loss, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor, Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor, Metastatic Testicular Seminoma, Stage II Testicular Cancer AJCC v8, Stage III Testicular Cancer AJCC v8
Interventions: Audiometric Test, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Sodium Thiosulfate Anhydrous; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Duarte, California

Conditions: Base of Tongue Cancer, HPV, Oropharyngeal Cancers, Tonsil Cancer
Interventions: Radiation; Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Clinton, Maryland

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions: Biopsy, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Gemcitabine, Medical Chart Review, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Radiation Therapy; Procedure · Drug · Other + 2 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Head and Neck Cancer
Interventions: ENI, ENI using IMRT with or without chemotherapy, INRT; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 4
States / cities: Iowa City, Iowa • Royal Oak, Michigan • Portland, Oregon + 1 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cancer
Interventions: Cancer and Aging: Reflections for Elders (CARE) Intervention, Social Work and Supportive Counseling (SWSC) Intervention; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 70 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: Retrospective Populations; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: DCIS, Ductal Breast Carcinoma In Situ, Stage 0 Breast Cancer
Interventions: 7-gene biosignature, Treatment recommendation surveys; Device · Other
Lead sponsor: PreludeDx; Industry
Eligibility: 30 Years to 85 Years · Female only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2036
U.S. locations: 30
States / cities: Scottsdale, Arizona • La Jolla, California • San Mateo, California + 25 more

Conditions: Cervical Cancer, Colo-rectal Cancer (dMMR/MSI-H CRC), Esophageal Adenocarcinoma, Esophageal Cancer, Gastric/GEJ, Gastro-Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Melanoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma, Ulcerative Colitis
Interventions: nivolumab, pembrolizumab; Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Oral Cancer
Interventions: Radiation; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2066
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Blood Cancer, Fungal Infection, Haematological Malignancy, Infectious Disease
Interventions: genotype-directed dosing with dosing software based on therapeutic drug monitoring; Other
Lead sponsor: The University of Queensland; Other
Eligibility: 2 Years and older
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: 2141-V11 Antibody; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Prostate Cancer, Prostate Cancer Metastatic
Interventions: Counseling Tool, Questionnaires; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Cisplatin, No treatment; Drug · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 59
States / cities: Duarte, California • La Jolla, California • Newport Beach, California + 43 more

Conditions: Colorectal Cancer; Lung Cancer
Interventions: Regorafenib Pill, TAS-102 pill, TATE and pembrolizumab; Drug
Lead sponsor: Teclison Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Prostate Cancer
Interventions: Sonablate HIFU device; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 100 participants
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Gastric Cancer, Hepatocellular Carcinoma
Interventions: Nivolumab Injectable Product, Trans-arterial tirapazamine embolization; Drug · Combination Product
Lead sponsor: Teclison Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 3
States / cities: Orange, California • Oklahoma City, Oklahoma • Milwaukee, Wisconsin

Conditions: Non-Small Cell Lung Cancer
Interventions: Lung Surgery, Radiation therapy; Procedure · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 40
States / cities: La Jolla, California • Aurora, Colorado • Colorado Springs, Colorado + 34 more

Conditions: Heptocellular Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT), Transarterial Radioembolization; Radiation
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cancer of the Pancreas, Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: Avutometinib, Defactinib, Stereotactic body radiotherapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

Quantitative MRI Assessment of Breast Cancer Therapy Response

Outcomes of Focal Ablation for Prostate Cancer

A New Psychotherapy Intervention for Older Cancer Patients

Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated With Radiation

The PREDICT Registry:

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Clinical and Molecular Features of Oral Premalignancy and Oral Cancer

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

HIFU for Focal Ablation of Prostate Tissue: An Observational Study

Combination of TATE and PD-1 Inhibitor in Liver Cancer

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Radioembolization Versus External Radiation Therapy

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma